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SUNITINIB IN ADVANCED CLEAR CELL RENAL CANCER: A
SINGLE CENTRE EXPERIENCE
G.S. Bruni, G. Facchini, V.R. Iaffaioli, C. Pisano, S. Pignata. Uro-
Gynecologic Department, National Cancer Institute of Naples, Italy
Renal cell carcinoma represents 2–3% of all cancer. New sys-
temic therapies have reached the market in the last 2 years. Sun-
itinib was found to be superior to IFN-a in a phase III trial in
metastatic renal cancer patients (mRC). Fatigue, gastrointestinal
and skin are the most frequently reported toxicities. Most of them
are easily solved with medical intervention or dose changes. In our
center we evaluated the sunitinib compliance and activity in an
unselected series of consecutive patients. In the first year after
sunitinib availability in Italy, 17 consecutive patients (13 male, 4
female, median age 62 years, range 40–81) with intermediate/poor
risk mRC were treated in our institution. Most frequent metastatic
sites were lung, pleura, bone, nodes and liver. Six out of 17 patients
were pretreated with cytokines. Overall 68 cycles of sunitinib were
given (range 1–11). Objective responses were observed in 5
patients (29%), while stable disease was observed in 4 patients
(23%) (overall clinical benefit 52%). Toxicity was as follows:
Results: Dose reductions were done in 9/17 patients (skin 1,
mucositis 4, hearth 2, fatigue 1, anemia 1), and in 3 cases treatment
was temporaneously interrupted due to toxicity. In conclusions,
sunitinib was confirmed to have significant activity in mRC. G3 tox-
icities are unfrequent, but often require dose modifications. Self-
training and internal guidelines in side effects medical treatment
and dose reduction rules seems crucial for an optimal use of suni-
tinib in unselected patients out of clinical trials.
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CYR61 DOWN-MODULATION SENSITIZES PROSTATE CANCER
CELLS TO ZOLEDRONIC ACID AND DOCETAXEL: A NEW ANTI-
CANCER STRATEGY
M. Caraglia a, M. Marra a, G. Meo a, S. Zappavigna a, B. Vincenzi b,
A. Baldi c, M. Rosolowski d, M. Loeffler d, G. Tonini b, D. Santini b, A.
Budillon a. aDepartment of Research, Experimental Pharmacology Unit,
National Institute of Tumours Pascale, Naples, Italy. bMedical Oncology,
University Campus Bio-Medico, Rome, Italy. cSecond University of
Naples, Italy. d Institute for Medical Informatics, Statistics and
Epidemiology, University of Leipzig, Germany
We have analysed the gene modulation induced by zoledronic
acid (ZOL) in androgen-resistant prostate cancer PC3 cells with
cDNA microarray platform to identify new molecular targets of
ZOL in prostate cancer. The gene coding for cysteine-rich, angio-
genic inducer, 61 (CYR61), often over-expressed in tumour cells,
resulted highly down-regulated with a fold-change of 5.58. There-
fore, we have studied the effects of different concentrations of
ZOL on CYR61 protein product and we have found that CYR61
protein expression was significantly decreased after exposure to
ZOL. The effect of ZOL on CYR61 expression was dose and time-
dependent and was due to a reduced transcriptional activity of
CYR61 promoter as demonstrated by transfection with a plasmid
encoding for luc-CYR61 promoter. Interestingly, other signal
transduction inhibitors or cytotoxic agents did not induce or
induced less effect on CYR61 modulation if compared to ZOL.
Moreover, ZOL reduced CYR61 expression through decreased acti-
vation of ras-raf-1-dependent pathway that was dependent from
isoprenylation inhibition since they were antagonized by the
addition of either farnesol or geranilgeraniol. Finally, we have
investigated the role of CYR61 in the regulation of growth inhibi-
tion and invasion/motility of PC3 cells using a shRNA for CYR61 in
order to down-regulate the expression of CYR61 protein. We have
found that shCYR61 enhanced inhibition of proliferation and
motility/invasion induced by ZOL by S-phase accumulation. In
the same experimental conditions, CYR61 protein down-regula-
tion potentiated the inactivation of the ras-dependent prolifera-
tion pathway. Since CYR61 was reported to be involved in the
resistance to taxanes we have evaluated if ZOL could sensitize
PC3 cells to Docetaxel (DTX). We have found a sequence-depen-
dent synergism induced by the combination between ZOL and
G1–2 (%) G3 (%)
Gastrointestinal 75 0
Skin 29 11
Mucositis 17 23
Hypotirodism 23 0
Anemia 11 0
Leukopenia 11 0
Hearth 6 6
Fatigue 35 6
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